DIAPH3 predicts survival of patients with MGMT-methylated glioblastoma

DIAPH3 predicts survival of patients with MGMT-methylated glioblastoma

BackgroundGlioblastoma is one of the most aggressive primary brain tumors, with a poor outcome despite multimodal treatment. Methylation of the MGMT promoter, which predicts the response to temozolomide, is a well-established prognostic marker for glioblastoma. However, a difference in survival can...

Full description

Bibliographic Details
Main Authors: Georges Chehade, Nady El Hajj, Mohamed Aittaleb, Maisa I. Alkailani, Yosra Bejaoui, Asma Mahdi, Arwa A. H. Aldaalis, Michael Verbiest, Julie Lelotte, Nuria Ruiz-Reig, Irene Durá, Christian Raftopoulos, Nicolas Tajeddine, Fadel Tissir
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Oncology
Subjects:
diaphanous formin
glioblastoma
mDia2
O(6)-methylguanine-DNA methyltransferase
MGMT methylation
survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1359652/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1359652/full

Similar Items